| References |
1. Matsumura Y, Yamamoto M, Nagao M, Tanaka M, Takakura S, Ichiyama S. In vitro activities and detection performances of cefmetazole and flomoxef for extended-spectrum β-lactamase and plasmid-mediated AmpC β-lactamase-producing Enterobacteriaceae. Diagn Microbiol Infect Dis. 2015 Dec 11. pii: S0732-8893(15)00438-1. doi: 10.1016/j.diagmicrobio.2015.12.001. [Epub ahead of print] PubMed PMID: 26782634. 2. Matsumura Y, Yamamoto M, Nagao M, Komori T, Fujita N, Hayashi A, Shimizu T, Watanabe H, Doi S, Tanaka M, Takakura S, Ichiyama S. Multicenter retrospective study of cefmetazole and flomoxef for treatment of extended-spectrum-β-lactamase-producing Escherichia coli bacteremia. Antimicrob Agents Chemother. 2015 Sep;59(9):5107-13. doi: 10.1128/AAC.00701-15. Epub 2015 Jun 22. PubMed PMID: 26100708; PubMed Central PMCID: PMC4538479. 3. Li LH, Yen MY, Ho CC, Wu P, Wang CC, Maurya PK, Chen PS, Chen W, Hsieh WY, Chen HW. Non-cytotoxic nanomaterials enhance antimicrobial activities of cefmetazole against multidrug-resistant Neisseria gonorrhoeae. PLoS One. 2013 May 21;8(5):e64794. doi: 10.1371/journal.pone.0064794. Print 2013. PubMed PMID: 23705013; PubMed Central PMCID: PMC3660602. 4. Doi A, Shimada T, Harada S, Iwata K, Kamiya T. The efficacy of cefmetazole against pyelonephritis caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae. Int J Infect Dis. 2013 Mar;17(3):e159-63. doi: 10.1016/j.ijid.2012.09.010. Epub 2012 Nov 8. PubMed PMID: 23140947. |
